Department of Oral Implants, School of Stomatology, State Key Laboratory of Military Stomatology & National Clinical Research Center for Oral Diseases & Shaanxi Engineering Research Center for Dental Materials and Advanced Manufacture, The Fourth Military Medical University, Xi'an, China.
Department of Oral Surgery, 920th Hospital of Joint Logistics Support Force, Kunming, China.
Drug Deliv. 2022 Dec;29(1):548-560. doi: 10.1080/10717544.2022.2036873.
The updating and optimization of drug delivery systems is critical for better behaviors of drugs, as well as for improving impaired implant osseointegration in diabetes. Numerous studies have reported the benefits of exendin-4 on diabetic bone, with the potential to enhance osseointegration in diabetes. To construct an appropriate sustained-release system of exendin-4 targeting implant osseointegration in diabetes, this study fabricated exendin-4-loaded microspheres using poly(lactic-co-glycolic acid) (PLGA) and chitosan. The morphology, size, encapsulation efficiency, and drug release behavior of microspheres were investigated. The bioactivity of drug-loaded microspheres on cell proliferation and osteogenic differentiation of diabetic BMSCs was investigated to examine the pharmacologic action of exendin-4 loaded into chitosan-PLGA microspheres. Further, the influence of microspheres on osseointegration was evaluated using type 2 diabetes mellitus (T2DM) rat implant model. After 4 weeks, the samples were evaluated by radiological and histological analysis. The results of experiments showed that the prepared exendin-4-loaded chitosan-PLGA microspheres have good properties as a drug delivery system, and the chitosan could improve the encapsulation efficiency and drug release of PLGA microspheres. In addition, exendin-4-loaded microspheres could enhance the proliferation and osteogenic differentiation of diabetic BMSCs. The results of experiments showed the exendin-4-loaded microspheres significantly improved the impaired osseointegration and bone formation around implants in T2DM rats without affecting blood glucose levels. Thus, the local application of exendin-4-loaded chitosan-PLGA microspheres might be a promising therapeutic strategy for improving the efficacy of dental implants in T2DM individuals.
为了改善糖尿病患者植入物骨整合受损的问题,对药物输送系统进行更新和优化至关重要。大量研究报道了 Exendin-4 对糖尿病骨骼的益处,有可能增强糖尿病患者的骨整合能力。为构建针对糖尿病植入物骨整合的 Exendin-4 靶向缓释系统,本研究采用聚乳酸-羟基乙酸共聚物(PLGA)和壳聚糖制备了载 Exendin-4 的微球。考察了微球的形态、粒径、包封率和药物释放行为。考察了载药微球对糖尿病 BMSCs 增殖和成骨分化的生物活性,以研究载药壳聚糖-PLGA 微球中 Exendin-4 的药效作用。进一步,通过 2 型糖尿病大鼠植入模型评价微球对骨整合的影响。4 周后,通过影像学和组织学分析评估样本。实验结果表明,所制备的载 Exendin-4 壳聚糖-PLGA 微球具有良好的药物传递系统性能,壳聚糖可提高 PLGA 微球的包封效率和药物释放。此外,载 Exendin-4 微球可增强糖尿病 BMSCs 的增殖和成骨分化。实验结果表明,载 Exendin-4 微球可显著改善 2 型糖尿病大鼠植入物周围受损的骨整合和骨形成,而不影响血糖水平。因此,局部应用载 Exendin-4 壳聚糖-PLGA 微球可能是提高 2 型糖尿病患者牙种植体疗效的一种有前途的治疗策略。